简体中文
产品中心
product| Name |
Chemical Name |
Cas No. |
Final API | Indication |
Scale | Purity or Assay |
| 四氢异喹啉 | 1,2,3,4-Tetrahydroisoquinoline | 91-21-4 | MULTI | NA | Commercial | ≥98.0% |
| N-乙酰基-4-哌啶酮 | N-Acetyl-4-piperidone | 32161-06-1 | MULTI | NA | Commercial | ≥98.0% |
| 2,6-二溴吡啶 | 2,6-Dibromopyridine | 626-05-1 | MULTI | NA | Commercial | ≥98.0% |
| 5-苯氧基异苯并呋喃-1-(3H)-酮 | 5-phenoxyisobenzofuran-1(3H)-one | 57830-14-5 | MULTI | NA | Commercial | ≥99.0% |
| (S)-2-(BOC-氨基)-3-[(S)-2-氧代-3-吡咯烷基]丙酸甲酯 | Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate | 328086-60-8 | PF-07321332帕罗韦德 | NA | Commercial | ≥99.0% |
| 溴乙腈 | Bromoacetonitrile | 590-17-0 | PF-07321332帕罗韦德 | NA | Commercial | ≥99.0% |
| (S)-4-苄基-2-唑烷酮 | (S)-4-Benzyl-2-oxazolidinone | 90719-32-7 | Aliskiren阿利克伦 | NA | Commercial | ≥99.0% |
| 2-乙基丁醇 | 2-Ethyl-1-butanol | 97-95-0 | Remdesivir瑞德西韦 | NA | Commercial | ≥99.5% |
| (S)-3-氰基-5-甲基己酸乙酯 | (S)-3-Cyano-5-methyl-hexanoic acid ethyl ester | 181289-39-4 | Pregabalin普瑞巴林 | NA | Lab completed | ≥97.0% |
| 2-[[(3aR,4S,6R,6aS)-6-氨基四氢-2,2-二甲基-4H-环戊并-1,3-二恶茂-4-基]氧基]-乙醇 (2R,3R)-2,3-二羟基丁二酸盐 | 2-{[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy}ethanol | 376608-65-0 | Ticagrelor替格瑞洛 | NA | Commercial | ≥99.0% |
| (1R,2S)-2-(3,4-二氟苯基)环丙胺 (R)-扁桃酸盐 | (1R,2R)-2-(3,4-difluorophenyl) cyclopropanamine(S)-(carboxylato(phenyl) methyl)holmium | 376608-71-8 | Ticagrelor替格瑞洛 | NA | Commerical | ≥99.0% |
| 4-氯吡咯并嘧啶 | 4-Chloropyrrolo[2,3-d]pyrimidine | 3680-69-1 | Tofacitinib托法替尼 & Ruxolitinib芦可替尼 & Baricitinib巴瑞替尼 & Abrocitinib阿布昔替尼 & Oclacitinib奥拉替尼 | NA | Commercial | ≥99.0% |
| 3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯胺 | 3-(4-Methyl-imidazol-1-yl)-5-trifluoro-methylphenylamine | 641571-11-1 | Nilotinib 尼罗替尼 | NA | Commercial | ≥98.0% |
| 二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮 | 10H-Dibenzo[b,f][1,4]thiazepin-11-one | 3159-07-7 | Quetiapine喹硫平 | NA | Commercial | ≥99.0% |
| 3-(甲氧基苯氧基)-1,2-环氧氯丙烷 | 1, 2-epoxy-3-(2-methoxyphenoxy)propane | 2210-74-4 | Ranolazine雷诺嗪 | NA | Commercial | ≥97.5% |
| 章胺盐酸盐 | Octopamine HCl | 770-05-8 | Ractopamine莱克多巴胺 | NA | Commercial | ≥98.0% |
| 覆盆子酮 | Raspberry ketone; 4-(4-hydroxyphenyl)-2-butanone | 5471-51-2 | Ractopamine莱克多巴胺 | NA | Commercial | ≥98.0% |
| 对甲基苯磺酰甲基异腈 | Tosylmethyl isocyanide | 36635-61-7 | MULTI | NA | Commercial | ≥99.0% |
| 2,8-双(三氟甲基)-4-羟基喹啉 | 2,8-bis(trifluoromethyl)quinolin-4-ol | 35853-41-9 | Mefloquine氟甲喹羟哌啶 | NA | Commercial | ≥97.0% |
| N-叔丁基-十氢异喹啉-3(S)-甲酰胺 | (S)-N-t-butyl decahydro-3-iso-quinolinecarboxamide | 136465-81-1 | Nelfinavir甲磺酸萘非那韦 & Saquinavir沙奎那韦 | NA | Commercial | ≥98.0% |
| (S)-2-苄基-N,N-二甲基氮杂环丙烷基-1-磺酰胺 | (S)-2-Benzyl-N,N-dimethylaziridine-1-sulfonamide | 902146-43-4 | Cobicistat考西司他 | NA | Commercial | ≥ 98.0% |
| N-甲基-2-异丙基-4-噻唑甲胺二盐酸盐 | 1-(2-isopropylthiazol-4-yl)-N-methylmethanamine dihydrochloride | 1185167-55-8 | Cobicistat考西司他 | NA | Commercial | ≥ 98.5% |
| N-[N-甲基-N-(((2-异丙基-4-噻唑基)甲基)氨基羰基]-L-缬氨酸锂盐 | N-[N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)aminocarbonyl]-L-valine lithium salt | 201409-23-6 | Ritonavir利托那韦 | NA | Commercial | ≥ 97.0% |
| ((5-噻唑基)甲基)-(4-硝基苯基)碳酸酯 | Carbonic acid 4-nitrophenyl 5-thiazolylmethyl ester | 144163-97-3 | Ritonavir利托那韦 | NA | Commercial | ≥98.0% |
| 3,5-二羟基戊苯 | 3,5-hydroxypentylbenzene | 500-66-3 | CBD大麻二酚 | NA | Commercial | ≥99.0% |
| 1,3,5-三溴苯 | 1,3,5-Tribromobenzene | 626-39-1 | Buflomedil丁咯地尔 | NA | Commercial | ≥99.0% |
| 原甲酸三丙酯 | Tri-n-propyl orthoformate | 621-76-1 | MULTI | NA | Commercial | ≥98.0% |
| 顺-4-苯硫基-L-脯氨酸 | cis-4-Phenylthio-L-proline | 81653-77-2 | Fosinopril福辛普利 | NA | Commercial | ≥98.0% |
| 2-氯-1-(3,4-二氟苯基)乙酮 | 2-Chloro-1-(3,4-difluoro-phenyl)-ethanone | 51336-95-9 | Ticagrelor替卡格雷 | NA | Commercial | ≥99.0% |
| 沙格列汀 | Saxagliptin | 945667-22-1 | 361440-67-7 709031-45-8 | CFDA USFDA | Ⅱ型糖尿病 | 98.0%~102.0% |
| 3-邻苯二甲酰亚胺丙醛 | 3-Phthalimidopropionaldehyde | 2436-29-5 | Atorvastatin阿托伐他汀 | NA | Commercial | ≥99.0% |
| 苄索氯铵 | Benzethonium chloride | 121-54-0 | 季铵盐类抗菌剂 | Commercial | ≥99.0% | |
| 枸橼酸托法替布 | Tofacitinib Citrate | 540737-29-9 | 3680-69-1 479633-63-1 | Lab completed | JAK通路抑制剂；类风湿性关节炎 | 98.0%~102.0% |
| 恩曲他滨 | Emtricitabine | 143491-57-0 | 147126-75-8 2022-85-7 147126-62-3 | USFDA WHO | HIV-1、乙肝 | ≥98.5% |
| 4-[2-(Boc-氨基)乙基]苯胺 | [2-(4-Aminoa-phenyl)-ethyl]-carbamic acid tert-butyl ester | 94838-59-2 | Mirabegron米拉贝隆 | NA | Commercial | ≥98.0% |
| 他扎罗汀 | Tazarotene | 118292-40-3 | NA | CFDA | 用于治疗银屑病、痤疮，并用于角化异常性疾病、毛囊皮脂腺疾病、皮肤癌前期病变 | 98.5%~101.5% |
| (1S,3S,5S)-3-(氨基羰基)-2-氮杂双环[3.1.0]己烷-2-甲酸 | (1S,3S,5S)-3-(Aminocarbonyl)-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester | 361440-67-7 | Saxagliptin沙格列汀 | NA | Commercial | Purity≥ 99.0% |
| 替格瑞洛 | Ticagrelor | 274693-27-5 | 51336-95-9 376608-71-8 376608-65-0 | Lab completed | 用于急性冠脉综合征 | ≥99.0% |
| (8-[2-羟基苯甲酰基]-氨基)辛酸钠 | Salcaprozate Sodium | 203787-91-1 | NA | Developing | 口服吸收促进剂 | ≥99% |
| 4-氯-7-甲苯磺酰基-7H-吡咯[2,3-D]嘧啶 | 4-Chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine | 479633-63-1 | Tofacitinib 托法替尼 | NA | Commercial | ≥99.0% |
| 雷诺嗪 | Ranolazine | 95635-55-5 | 2210-74-4; 1131-01-7; 5294-61-1; | Developing | 治疗慢性心绞痛药 | ≥99% |
| 甲磺酸达比加群酯 | Dabigatran Etexilate Mesylate; Pradaxa | 872728-81-9 | 212322-56-0 | Lab completed | 抗凝血药物 | 98.0%~102.0% |
| 二碘甲烷 | Diiodomethane | 75-11-6 | MULTI | NA | Commercial | Purity≥99.0% (stabilized with Copperchip) |
| 氯碘甲烷 | Chloroiodomethane | 593-71-5 | MULTI | NA | Commercial | Purity≥98.0% (stabilized with Copperchip) |
| 2-(4-(2-氯乙基)苯基)-2-甲基丙酸 | 2-(4-(2-Chloroethyl)phenyl)-2-Methylpropanoic acid | 2199440-16-7 | Bilastine比拉斯汀 | NA | Commercial | Purity≥98.0% |
| 4-(1H-苯并[D]咪唑-2-基)哌啶-1-羧酸叔丁酯 | Tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate | 953071-73-3 | Bilastine比拉斯汀 | NA | Commercial | Purity≥98.0% |
| [1-(叔丁氧羰基)哌啶-4-基]碘化锌 | (1-(tert-butoxycarbonyl)piperidin-4-yl)zinc(II) iodide | 807618-13-9 | NA | NA | Lab completed | 0.95M in DMA |
| 18-冠醚-6 | 18-Crown-6 | 17455-13-9 | MULTI | NA | Commercial | Purity≥99.0% |
| 2-氯-4-(1-哌啶甲基)吡啶 | 2-Chloro-4-((Piperidin-1-yl)Methy)Pyridine | 146270-01-1 | MULTI | NA | Commercial | Purity≥99.0% |
| 7-氯-2-氧代庚酸乙酯 | Ethyl 7-chloro-2-oxoheptanoate | 78834-75-0 | Cilastatin西司他丁 | NA | Commercial | Purity≥98.0% |